Lv6
3086 积分 2021-08-29 加入
Accelerating adoption of new approach methodologies in regulatory decision making: an industry perspective
15小时前
待确认
Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review
15小时前
待确认
Nonclinical Development of Biologics, Vaccines and Specialty Biologics
19小时前
待确认
Confirmatory Evidence Used in Non‐Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020–2023
1天前
待确认
Improving the assessment of the probability of success in late stage drug development
1天前
待确认
Optimal decision‐making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival
1天前
待确认
In this Issue
1天前
待确认
The Role of Enhanced Analytical Procedure Development in Facilitating Post-Approval Changes Via Established Conditions
14天前
已完结
Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop
14天前
已完结
Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals During COVID-19
15天前
已关闭
皖公网安备34019202002308
